==Madison Square Garden Sports (MSGS) and Madison Square Garden Entertainment (MSGE)

MSGS owns the New York Knicks (NBA), New York Rangers (NHL), and related assets (minor league teams, training facilities, etc.).

It became public through a spin-off in 2015 (originally trading as MSG) from what was then the broader Madison Square Garden Company.

In 2020, it spun off its entertainment assets (including Madison Square Garden arena operations) into a separate public company (now MSGE / Sphere Entertainment).

MSG Sports is actively pursuing a proposed tax-free spin-off to separate the Knicks and Rangers businesses into two distinct publicly traded companies.

 

==Nu Holdings Ltd. (NU) : 5-year performance

 

Nubank (also known outside Brazil as Nu) is Latin America's largest digital bank and fintech company, serving over 135 million customers across Brazil, Mexico, and Colombia. Headquartered in São Paulo, Brazil, it operates entirely through a mobile app, offering no-fee credit cards, digital accounts, personal loans, and investments. 

• https://international.nubank.com.br/about/
• Ticker: NU

Core Offerings and Features

Nubank was designed to disrupt traditional Latin American banking by eliminating account maintenance fees, cutting out physical branches, and using data-driven artificial intelligence to provide rapid approvals and strong customer support. 

• Digital Accounts: Features high-yield daily liquidity and digital transfer options like Pix in Brazil.
Credit Cards: Initially launched as a no-annual-fee credit card, it acts as a primary entry point for millions of unbanked and underbanked individuals.
Other Services: Personal loans, life insurance, SME business accounts, and investment products.

Growth and Expansion

Founded in 2013 by David Vélez, Cristina Junqueira, and Edward Wible, Nubank has become one of the fastest-growing and most valuable financial institutions in emerging markets. 

ERock, Inc. (EROC) began trading on the NYSE on Wed 10 June 26

ERock (formerly Enchanted Rock), provides reliable, large-scale onsite power solutions (natural gas generators, microgrids, bridge/backup/dispatchable power). 

It primarily serves data centers, utilities, and large commercial & industrial (C&I) customers, with major footprints in California and Texas. 

• Sector: Industrials
• Industry: Specialty Industrial Machinery
• Full Time Employees: 440
• Founded in 2006 
• HQ in Houston, Texas
• https://erock.com

Pricing: $21.50 per share (midpoint of the $20.00–$23.00 range). 

Shares offered: 27,906,977 shares of Class A common stock, raising approximately $600 million in gross proceeds.

The company is experiencing heightened demand from AI as data centers require massive, reliable power for AI workloads and GPU clusters. Its quick-response natural gas generators provide immediate, dispatchable power to support AI infrastructure expansion while grid capacity lags, making ERock a critical partner for AI companies needing rapid power deployment.

At the center of Erock's platform is RockBlock, a modular, distributed generator string that incorporates the company's proprietary natural gas engine, scales in 0.5 MW increments from 1.5 MW to 3.5 MW per RockBlock, and is assembled in-house. The generator technology is also supported by its Granite Software Ecosystem. 

Over the past decade, the company has built relationships with leading data center and AI firms, such as Microsoft (MSFT), Wistron, and Foxconn; electric and gas utilities, such as Entergy (ETR), and ComEd (EXC); and C&I customers, such as H-E-B and Walmart (WMT).  

==Robo.ai Inc. (AIIO)

 

NWTN Inc. did not conduct a traditional public offering; instead, it went public via a merger with the SPAC East Stone Acquisition Corporation on November 14, 2022. 

In August 2025, the company officially rebranded as Robo.ai Inc. and trades on the Nasdaq under the ticker AIIO. 

The company has undergone several major strategic shifts and corporate updates: 

• Strategic Rebrand & Pivot: Formerly a new energy vehicle (NEV) specialist headquartered in Dubai, the company transitioned its focus to AI, edge processing, and robotics platforms . 
• Corporate Actions: In April 2026, the company implemented a 1-for-20 reverse stock split to maintain compliance with Nasdaq's US$1.00 minimum bid price . 
• Recent Compliance: Robo.ai received official notification from Nasdaq that it successfully regained compliance with the minimum bid price requirement . 
• Recent Acquisitions: Robo.ai finalized the 100% equity acquisition of Neurovia AI, an AI visual data compression firm . 

Zura Bio (ZURA): 3-year performance

Zura Bio, the clinical-stage immunology company entered the public markets on March 21, 2023, by completing a reverse merger with the special purpose acquisition company (SPAC) JATT Acquisition Corp.

 

Zura Bio develops therapeutic medicines for immune and inflammatory disorders, with a pipeline that includes product candidates like tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880).

• Founded 2022
• Website zurabio.com
• Employees 40
• https://zurabio.com/

IPO: March 21, 2023

===Filana Therapeutics (FLNA)

Pain Therapeutics, Inc. was a drug development company that rebranded as Cassava Sciences, Inc. in 2019. Following multiple regulatory rejections for its chronic pain drug Remoxy, the company shifted its focus to neurodegenerative diseases. In early 2026, the corporation further rebranded as Filana Therapeutics.

        

Origins (1998): Founded by Remi Barbier, the company originally focused on non-addictive pain therapies and abuse-deterrent opioids. 

Pain Programs: Its primary pipeline candidates included Remoxy (an abuse-deterrent oxycodone) and Oxytrex. After repeated Complete Response Letters (CRLs) from the FDA, the company abandoned its pain pipeline to focus on neurological conditions.

PTI-901 aimed to treat irritable bowel syndrome. 

The company had no drug approved as of 2021, and no product revenues between 2013 and 2021; with 25 employees, the company's stock was the sixth-best performing in 2021 before falling after concerns over simufilam research.

Alzheimer's Drug Failure: The biotech discontinued all trials of simufilam for Alzheimer's disease after the drug missed all primary and secondary endpoints in late-stage Phase III studies.( late 2024).

Scrutiny and Investigations: The drug and its foundational data were subject to intense scrutiny. The SEC sued the company for allegedly publishing misleading data , and a federal grand jury indicted a former scientific advisor to the company for allegedly submitting false data regarding the drug's mechanism .

Corporate Settlement & Leadership Changes: Following the data controversy, several top executives—including former CEO Remi Barbier—resigned. Under new CEO Richard Barry, Cassava paid a $40 million fine to the SEC to settle misleading claims , and the DOJ subsequently closed its probe.

The company initially worked on three drugs: the pain drugs Oxytrex and Remoxy, and 

The Pivot to Filana Therapeutics: Shedding its troubled past, the company officially changed its name to Filana Therapeutics in March 2026. The biotech now trades under the ticker symbol "FLNA" and has shifted its developmental focus toward central nervous system (CNS) disorders, specifically exploring simufilam as a potential treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy.

==Uber-backed Lime has filed for an IPO

Lime, founded ‌in 2017 and helmed by former Uber executive Wayne Ting, operated in about 230 cities across 29 countries, as of December 31, 2025.

Lime, which ⁠provides short-term rentals of electric bikes and scooters, and some selling shareholders are looking to sell about 6.96 million shares in total, priced between $24 and $26 apiece, aiming to raise ‌up to $181.9 million.

Key Details:

• Ticker: LIME (planned for Nasdaq)
• Price range: $24–$26 per share
• Shares offered: ~6.96 million total (mostly by the company, some by selling shareholders)
• Expected raise: Up to ~$182 million (at midpoint)
• Valuation: Targeting up to ~$1.66–1.8 billion (post-IPO)
• Underwriters: Led by Goldman Sachs and JPMorgan
• Roadshow: Launched around June 22, 2026; pricing expected the week of June 29, 2026 (trading shortly after)

The firm outlined in its prospectus that ⁠it has incurred net losses in every year since its inception. For 2025, it posted a net loss of $59.3 million ​on revenue of $886.7 million.

The company, which filed for its public offering last month, has applied to list on the ​Nasdaq under the ticker symbol “LIME.”

Goldman Sachs, ‌J.P. Morgan and Jefferies are among the underwriters for the offering. ​

Legend Biotech (LEGN) prices offering of 7.7 mln ADSs at $29.35 per ADS

• Legend Biotech prices 7.7 million ADS underwritten offering at $29.35 each for expected gross proceeds of approximately $226 million
•  Legend Biotech (NASDAQ: LEGN) went public on June 5, 2020, raising approximately $424 million in its initial public offering (IPO). The company originally offered 18.4 million American Depositary Shares (ADS) at a price of $23.00 per share.
• https://legendbiotech.com/

---Aerospace parts maker Doncasters targets $4.4 billion valuation in US IPO

June 15 (Reuters) - Doncasters is targeting a valuation of up to $4.43 billion in its U.S. initial public offering, ​becoming the latest aerospace firm to test investor appetite for new ‌listings.

The Derby, United Kingdom-based company is seeking up to $746.7 million in the IPO by offering 23.3 million shares priced between $28 and $32 apiece, it said on Monday.

Ticker: DPC

Exchange: NYSE

Target Deal Size: ~ $700 million

Share Price Range: $28 to $32

Target Valuation: Up to $4.43 billion at the high end of the range

Lead Bookrunners: Jefferies and Morgan Stanley

The U.S. IPO market ​has gained momentum after a choppy start to the year, with aerospace ​and defense as well as AI infrastructure themes dominating the ⁠lineup since April.

Doncasters will follow Arxis (ARXS.O), opens new tab and Applied Aerospace & Defense (AADX.N), opens new tab, fellow aerospace parts ​makers that have gone public in New York since April.

Company Overview

• History: Founded in 1778 in Sheffield, UK, the company manufactures high-precision alloy components (like turbine blades and vanes) for the "hot zones" of aerospace engines and industrial gas turbines. 
• Clients: Serves major original equipment manufacturers (OEMs) including GE Aerospace, Honeywell, Pratt & Whitney, and Rolls-Royce. 
• Financials: In 2025, the company reported revenue of $837 million, though it remains loss-making due to heavy investments in expanding capacity.